The invention is effective for the treatment and relief of a cough caused by posterior nasal secretion using the combination of oxymetazoline and ipratropium. The stated active agents in the combination according to the invention have been used and marketed separately with different uses to those according to the invention. The oxymetazoline is market for eliminating nasal secretion and congestion (blockage) and the ipratropium bromide is marketed for the purpose of dilating the bronchi in asthmatic patients and patients with chronic obstructive pulmonary disease although it has also be used experimentally for reducing nasal secretion. Both active agents together or separately have not yet been used as intranasal antitussives. The cough caused by posterior nasal secretion is the most common cause of a cough in humans of any age and this invention is effective for the treatment and relief of said symptom.
